标题: Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve [打印本页] 作者: StephenW 时间: 2011-12-29 07:41 标题: Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve
Gut Liver. 2011 Dec;5(4):478-85. Epub 2011 Nov 21.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22195247
Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve
chronic hepatitis B patients at 48 weeks.
Wang LC, Chen EQ, Zhu XF, Xiong
ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. SourceCenter of Infectious
Diseases, West China Hospital, Sichuan University, Chengdu, China.
Abstract
BACKGROUND/AIMS: To reveal possible factors predicting the effect of
adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and
optimize the utilization of ADV. METHODS: In total, 168 treatment-naïve
CHB patients were enrolled, including 117 hepatitis B e antigen
(HBeAg)-positive patients and 51 HBeAg-negative patients who met the
inclusion criteria. All patients were treated with ADV 10 mg per day for 48
weeks. Multiple logistic regression analyses were used to investigate
baseline factors, and responses at weeks 12 and 24 were analyzed as
predictive values. RESULTS: Multiple regression analyses showed that
baseline HBeAg status and HBV DNA levels significantly affected the
virological response (VR) (p<0.05), baseline ALT levels were an independent
predictor of serological response (SR) (p<0.05) and the body mass index
(BMI) may affect the biochemical response (BR) (p<0.05). There was a
statistically significant difference in the VR and SR between patients with
a primary nonresponse (PNR) at week 12 and those with a VR at week 12
(p<0.01). Additionally, the VR was significantly different between patients
with HBV DNA lower than 10(3) copies/mL at week 24 and those with greater
than 10(3) copies/mL (p<0.01).
CONCLUSIONS: Patients with negative HBeAg,
lower HBV DNA levels and higher ALT values at baseline are more suitable
for ADV treatment, whereas patients with lower BMIs may be more amenable to
ALT normalization. Adjustments for treatment strategy should be considered
if PNR at week 12 or HBV DNA =10(3) copies/mL at week 24 is observed. 作者: StephenW 时间: 2011-12-29 07:42